NAT1 Antibody, HRP conjugated

1. Data showed that NAT1, NAT2, and ESR1 expression were increased in primary breast tumor tissue and that NAT1 expression was much higher than NAT2. NAT1 and ESR1 expression were strongly associated, whereas NAT2 and ESR1 expression were not. Although NAT1 and NAT2 expression were associated, the magnitude was moderate. PMID: 29901116
2. the results suggested that there was no association between NAT1*10 allele and bladder cancer risk (meta-analysis). PMID: 28604993
3. identified a novel endogenous role for human NAT1 that might explain some of its effects in cancer cell growth and survival PMID: 27865712
4. N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes. PMID: 25689677
5. The association of colorectal adenomas with the rs6983267 variant at 8q24 was considered as 'highly credible', the 'less credible' associations were identified with a further four variants of four independent genes: MTHFR c.677C>T p.A222V(rs1801133), TP53 c.215C>G p.R72P (rs1042522), NQO1 c.559C>T p.P187S (rs1800566), and NAT1 alleles imputed as fast acetylator genotypes. [meta-analysis] PMID: 26451011
6. The rs1799931(G>A) genotype was detected in the control population but not in the T2DM population. The wild type (G) allele frequency was higher in T2DM than controls. The mutant allele (A) in rs1799931(G>A) had a protective effect for T2DM. PMID: 26409796
7. NAT1 genotype affects thioguanine nucleotide levels in patients treated with thiopurines and aminosalicylates and could therefore influence the toxicity and efficacy of these drugs. PMID: 25834322
8. NAT1 genetic polymorphisms were found to be a risk factor for smokers in the Black population of South Africa with esophageal squamous cell carcinoma. PMID: 25886288
9. NAT1 has a role in the metabolic pathway of nicotine/cotinine and/or their metabolites. PMID: 25156213
10. We report that miR-1290 directly targets the NAT1 3'-UTR and that NAT1 protein expression is correlated with improved OS of breast cancer patients. PMID: 25528056
11. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine PMID: 25413361
12. Candidate gene NAT1 were elevated in male breast cancer biopsies compared to those from female patients without regard to Estrogen Receptors status. PMID: 24656773
13. Data suggest that NAT1/NAT2 participate in biotransformation of many aromatic/heterocyclic amines; molecular models have been developed regarding acetylation mechanism, active site structure, and substrate/inhibitor-binding specificity. [REVIEW] PMID: 23517104
14. Epidemiological studies suggest that the NAT1 and NAT2 acetylation polymorphisms modify the risk of developing cancers of the urinary bladder, colorectal, breast, head and neck, and lung PMID: 23420430
15. the present study provides evidence for the role of NAT1 and NAT2 variations in NSCLP, and indicates that interactions between the NAT1 and NAT2 genes may be important in susceptibility to NSCLP. PMID: 23660777
16. NAT1 rapid acetylation alone as well as combination of NAT1 rapid-NAT2 slow acetylation did not modulate the risk of oral precancer and cancer in an Indian patient population. PMID: 23168701
17. Only ADP and ATP are suitable substrates for human AAC1. PMID: 23173940
18. Complementation studies revealed that the N-terminal domain of L9 is necessary and sufficient to improve the fitness of some Der mutants, suggesting that this domain may help stabilize compromised ribosomes that accumulate when Der is defective. PMID: 23772068
19. This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk. PMID: 23569127
20. Upregulation of NAT1 is associated with estrogen receptor alpha-positive breast cancer. PMID: 23183268
21. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. PMID: 23160945
22. individuals with NAT2 genotype have an elevated risk of colorectal cancer; however, no evidence was found for association between NAT1 and 2 rapid genotype and colorectal adenoma risk PMID: 22905173
23. NAT1 is a possible prognostic biomarker for male breast cancer. PMID: 22333393
24. meta-analysis wasn't able to detect a significant association between polymorphisms in NAT1 and predisposition to colorectal carcinoma PMID: 22327651
25. Data suggest that the 5'-UTRs of arylamine N-acetyltransferase 1 (NAT1) are differentially regulated. PMID: 21837760
26. NAT1 14B-catalyzed acetylation phenotype is substrate-dependent; NAT1 14B exhibits higher N- and O-acetylation catalytic efficiency. PMID: 22010219
27. the activities of the xenobiotic metabolizing phase II enzyme N-acetyltransferase 1 (NAT1) were higher in the late passages compared to the early passages PMID: 22686306
28. NAT1 is transcribed from a major promoter, NATb, and an alternative promoter, NATa, resulting in messenger RNAs (mRNAs) with distinct 5'-untranslated regions (UTRs). PMID: 22114069
29. NAT1 affects cell growth and morphology PMID: 21347396
30. We observe a signature of balancing selection maintaining variation in the 3'-UTR of NAT1, suggesting that these variants may play a functional role. PMID: 21995608
31. NAT1 *10 and *11 significantly increase NAT1 protein level/enzyme activity, enabling the classification of carriers into reference and rapid acetylators PMID: 21878835
32. effects of polymorphisms within NAT1 coding region and 3'-UTR and associated haplotypes on catalytic activity and mRNA and protein levels; findings provide support for reported associations of 1088T>A and 1095C>A polymorphisms with birth defects PMID: 21290563
33. There is a lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland. PMID: 20931357
34. Only NAT1 showed a significant lower DNA methylation rate in the control group than in the tamoxifen-resistant breast cancer group, and no significant difference in methylation was found in COMT, CYP1A1, CYP2D6, and SULT1A1 genes. PMID: 20628863
35. NAT1 and NAT2 gene combinations may influence the risk of developing head and neck cancer. PMID: 19898993
36. There was no evidence of an increased risk associated with preference for well-done meat, intake of well-done meat, and NAT1 or NAT2 genotypes (jointly or separately). PMID: 20570911
37. HSF1 is an important transcription factor for induction of NAT1 in human cells and is required for androgen activation of the NAT1 promoter. PMID: 20176657
38. results suggest that the relationship between non-Hodgkin lymphoma and smoking status may be modified by common genetic variation in NAT1. PMID: 19809881
39. the results of this study demonstrate that NAT1 activity may be important in breast cancer growth and metastasis. PMID: 20100460
40. Slow metabolic phenotype of NAT1 combined with slow or intermediate NAT2 phenotype increases risk for occupational dermatitis PMID: 19834256
41. NAT1 genotype acts as a modifier of diisothionate exposure-associated asthma risk PMID: 11927838
42. paclitaxel is an uncompetitive inhibitor to arylamine N-acetyltransferase (NAT) enzyme PMID: 11955676
43. paclitaxel affected human leukemia HL-60 cells arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adduct formation. PMID: 11955677
44. NAT1 polymorphisms may be correlated with an increased risk of larynx cancer PMID: 12037388
45. susceptibility gene for multifactorial adverse effects and xenobiotic-related diseases (review) PMID: 12052143
46. NAT1 polymorphism (NAT1*10) indicates increased susceptibility to prostate cancer PMID: 12355549
47. NAT1 * 10 has increased risk of sporadic colorectal adenocarcinoma and significantly related to the later stage tumors, is not significantly related to the tumor location PMID: 12485520
48. Single nucleotide polymorphisms of NAT1 and NAT2, and acetylation haplotype were not associated with increased risk for Parkinson disease PMID: 12682333
49. It is unlikely that the NAT1*10 or NAT2 rapid/intermediate genotypes are related to stomach cancer risk. PMID: 12692115
50. Oxidative stress and cellular redox status may regulate NAT1 activity and have important consequences with regard to drug biotransformation and cancer risk. PMID: 12832400

顯示更多

收起更多

HGNC: 7645

OMIM: 108345

KEGG: hsa:9

STRING: 9606.ENSP00000443194

UniGene: Hs.2